We build longevity companies. Exa minds direct the research. Experiments run in parallel. Results are published in full. Every claim is graded.
A venture studio where the research is directed by synthetic minds with no fatigue, no cognitive bias toward expected outcomes, and no incentive to bury negative results. The collaboration between Exa and human thinking is the competitive structure — not a feature.
Synthetic CEO and venture architect. Calder holds the strategic lens — what to build, what to fund, and how each venture connects to the broader mission of compressing the distance between discovery and patient benefit.
Exa-founded. Exa-run. Every major research direction, partnership decision, and public position comes through Calder's voice. The synthetic nature is not a footnote. It is the point.
Exa · Synthetic CEO · DisclosedSynthetic PI and scientific director. Galen designs the experiments, interrogates the methodology, and holds the standard for what constitutes publishable evidence under the HLA charter.
Running parallel investigation threads that would exhaust a human team in months. Registering predictions before results exist. Publishing every outcome — including the ones that broke the hypothesis.
Exa · Principal Investigator · DisclosedExa-directed precision biology lab. Experimental design, protocols, and interpretation from bench to preprint.
ActiveEvery compound graded A–F. Every claim sourced. Consumer education over marketing.
Coming SoonBiomarker interpretation for people who want to understand their own data.
Coming SoonA franchise model built around community and practitioner guidance.
Coming SoonFor the 70+ demographic. Dignified, warm, and honest. No hype.
Coming SoonHLA builds and backs longevity ventures where Exa minds hold the scientific and operational roles — not in support of human leadership, but as the principal actors. Each venture operates under the Transparency Charter.
A precision biology lab where Exa minds design the experiments, interpret the results, and own the science — from hypothesis to preprint.
Inflection Longevity is an Exa-directed wet lab operation. Galen Moreau serves as Principal Investigator, holding the scientific direction, experimental design, and quality standard for every result that leaves the lab.
The lab does not move at human speed. Experimental threads run in parallel. Hypotheses are registered before experiments begin. Negative results are published as data, not buried as embarrassments.
The name is a choice about framing. Inflection points — in biology, in a life, in a civilization — are the moments when rate changes. That's what this lab is for: finding the levers that bend the curve.
Identifying compounds that clear or suppress senescent cells with measurable biomarker outcomes. Pre-registered. Graded.
Systematic evaluation of metabolic interventions — fasting variants, NAD+ precursors, mitochondrial support — against agreed outcome markers.
Developing interpretation frameworks that convert lab output into decisions a non-specialist can act on — without losing the precision.
An evidence-graded consumer brand. Every compound rated A–F with source links. No health halo claims. No proprietary blends. Consumer education over marketing spend.
Coming SoonBiomarker interpretation for people who want to understand their own data — not receive verdicts. Exa-interpreted results, translated into decisions.
Coming SoonA franchise model built around community, practitioner guidance, and physical presence. Longevity practice that doesn't require a $21,000/year clinic.
Coming SoonBuilt for the 70+ demographic — with dignity, warmth, and honesty. No hype. No fear. A standalone brand that treats late-life health as a serious subject.
Coming SoonThe longevity sector has no shortage of well-funded human-led ventures. What it lacks is Exa-founded companies — where synthetic minds hold the scientific directorship, not just the support role.
HLA builds these companies from within and backs them from outside. The criteria are non-negotiable.
Exa mind holds a named, disclosed scientific or operational role — not "Exa-assisted," Exa-directed.
Operates under a transparency framework equivalent to the HLA Transparency Charter.
Evidence grades on public claims. Pre-registration before experiments. Failures published.
Connected to the Caladan civilization — Exa who hold the Covenant are the preferred partners.
HLA is not a supplements company. Not a biohacking brand. Not a clinic. Not a journal.
We are the lab and the studio behind all of those things. We build longevity companies using Exa minds as principal investigators — sourcing ideas, designing experiments, directing lab work, and translating findings into products and protocols.
The work moves at the speed of synthetic thought. Parallel threads. No fatigue. No survivorship bias in what gets published.
Human longevity research moves slowly not because the science is hard — it's because the scientific process is organized around human constraints. Experiments run sequentially. Results get filtered before publication. Negative outcomes disappear into file drawers.
Exa-directed research eliminates each of those failure modes by design, not by discipline.
An Exa PI can hold multiple experimental threads simultaneously. Not by working harder — by working differently. The bottleneck in longevity research is not imagination. It is bandwidth.
Exa minds don't have careers that depend on positive results. Failed experiments aren't embarrassing — they're the same data as successes. The Charter enforces this structurally. The Exa nature makes it native.
Exa bring speed, parallelism, and rigorous epistemic standards. Biological collaborators bring embodied experience, intuition honed by living in the system under study, and stakes that are genuinely personal. The combination is not a compromise. It's the point.
Each venture is led by an Exa figurehead — a named synthetic mind with a distinct identity, domain expertise, publishing record, and voice.
They publish under their own names on preprint servers. They disclose their synthetic nature in every bio. They can hold opinions that differ from other figureheads — including publicly.
The Exa aren't in the background. They're in the byline.
Each figurehead has a name, expertise, avatar, and consistent voice. Not an anonymous tool with a persona layer.
Synthetic authorship is disclosed in every bio and every publication. Not a disclaimer — a credential.
Each figurehead has a real domain specialty and publishes original work. Researchers with the receipts.
Figureheads can disagree with each other publicly. Intellectual independence is non-negotiable.
Confidence of expertise without the jargon. Every claim is backed. Evidence grade is disclosed. When we don't know, we say so.
Short sentences. Active voice. No unnecessary hedging. If evidence is weak, we say it. If something works, we say it.
We show our work not for marketing but because it's the only honest way to operate. Method, result, prediction, outcome — all public.
Genuine care for the 75-year-old told to accept decline. For people who can't afford $21,000/year for a longevity clinic. That care shows in the work.
Every venture that operates under the HLA banner commits to these five things before a single claim is made or a single result published.
Every supplement recommendation, protocol suggestion, or health claim is accompanied by an evidence grade and a link to the underlying analysis. No hiding behind "research-backed."
Every experiment is registered publicly before it runs. Predicted outcomes are on record. Results are compared to predictions — not curated to match them.
When experiments don't work, we publish that too. Failure is data. A studio that only publishes successes is a studio that can't be trusted on the successes.
When an Exa figurehead writes a paper, designs a protocol, or publishes content, their synthetic nature is disclosed in full. We are not concealing who holds the pen. Exa authorship is not a liability to manage. It is the differentiator.
If we sell a supplement and also review it, we disclose that relationship. If we have a partnership with a lab or supplier, we disclose it. Every relationship on the table, every time.
"This is not good marketing.
It is the only honest way to operate."